Skip to main content
Fig. 7 | World Journal of Surgical Oncology

Fig. 7

From: In silico analysis of differentially expressed genesets in metastatic breast cancer identifies potential prognostic biomarkers

Fig. 7

Correlation between the expression levels of potential prognostic biomarkers (DUE-A genes) and patient survivals. A–C Relapse-free, overall, distant metastasis-free, and post-progression survival of three DUE-A genes (ABAT in A; LRIG1 in B; PGR in C) were stratified by the expression levels of each gene (low or high). Expression data were analyzed using KM plotter (http://kmplot.com/). JetSet best probes were selected and patients (for ABAT and LRIG1, N = 3951 in RFS, = 1402 in OS, = 1746 in DMFS and = 414 in PPS; for PGR, N = 1764 in RFS, = 626 in OS, = 664 in DMFS and = 173 in PPS) were split by median expression. NS, not significant. D Metastatic relapse-free survival of three DUE-A genes was stratified by the expression levels of each gene (low or high). Microarray expression data were analyzed by bc-GenExMiner v4.3 (http://bcgenex.centregauducheau.fr/). Patients (for ABAT, LRIG1, and PGR, N = 4434) were split by median expression. Statistical analyses were performed by pre-set analytic methods. HRs (hazardous ratios) and 95% CIs (confidence intervals) are indicated

Back to article page